Document:

Form of Common Stock Purchase Warrant, effective as of April 13, 2005

 Exhibit 4.6 
  

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS THEREUNDER AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. 
  
 RELIANT PHARMACEUTICALS, INC. 
  

COMMON STOCK PURCHASE WARRANT 
  

			
	Warrant No.                     	 	Dated of Issue: April     , 2005

  
 Reliant
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received,
[                                ], or its permitted registered successors and
assigns (“Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of
[                    ] shares of common stock, $.01 par value per share (the “Common Stock”), of the Company (each such
share, a “Warrant Share” and all such shares, the “Warrant Shares”). The initial “Exercise Price” for Warrant Shares shall be $20.00/share and shall be subject to adjustment from time to time as
provided in Section 7. The Holder may acquire Warrant Shares under this Warrant at such times as is provided for in Section 3(a) hereof. 
  
 This Warrant is issued by the Company to the Holder in connection with that certain Third-Lien Credit and Guaranty Agreement, dated as of April
    , 2005, among the Company, certain subsidiaries of the Company, various lenders, and Goldman Sachs Credit Partners, L.P. (the “Third-Lien Credit Agreement”). 
  
 This Warrant shall be subject to the following terms and conditions:

  
 1. Registration of Warrant. The Company shall register
this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. Except as provided in Section 2 below, the Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, and the Company shall not be affected by notice to the contrary. 
  
 2. Transferability; Registration of Transfers and Exchanges.

  
 (a) Each Holder of this Warrant acknowledges that this
Warrant, the Warrant Stock and the Common Stock of the Company have not been registered under the Securities Act 

 
of 1933, as amended, (the “Securities Act”). Each Holder agrees not to sell, pledge, distribute, offer for sale, transfer or otherwise
dispose of this Warrant, any Warrant Shares issued upon its exercise or any other Common Stock of the Company in the absence of (i) an effective registration statement under the Securities Act as to this Warrant, such Warrant Shares or such Common
Stock and registration or qualification of this Warrant, such Warrant Shares or such Common Stock under any applicable United States federal or state securities law then in effect, or (ii) an opinion of counsel, satisfactory to the Company, that
such registration and qualification are not required. Each certificate or other instrument for Warrant Shares issued upon the exercise of this Warrant shall bear a legend substantially to the foregoing effect. 
  
 (b) Subject to the provisions of Section 2(a) hereof and the terms of
the Stockholders’ Agreement, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed Form of Assignment attached hereto at the principal office of the Company. Transfer
of the Warrant, in whole or in part, shall not effect the Holder’s interest and/or rights in and obligations under the Third-Lien Credit Agreement. 
  
 (c) The Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of
Assignment attached hereto duly completed and signed, to the Transfer Agent or to the Company at its address for notice set forth in Section 10. Upon any such registration or transfer, a new warrant to purchase Common Stock, in substantially the
form of this Warrant (any such new warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so
transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a holder of a Warrant. 

 
 (d) This Warrant is exchangeable, upon the surrender hereof by the Holder
to the office of the Company at its address for notice set forth in Section 10 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder. Any such New Warrant
will be dated the date of such exchange. 
  
 (e) This Warrant has
been issued subject to certain investment representations of the original Holder set forth in the Third Lien Credit Agreement and may only be transferred or exchanged in compliance with the transfer restrictions contained therein. 
  
 (f) As a condition to the initial exercise of this Warrant (or any New
Warrant), Holder shall execute a joinder to the Stockholders’ Agreement of the Company, if any, as then in effect (the “Stockholders’ Agreement”), agreeing to be bound as a stockholder holding Common Stock thereunder.

  
 (g) The Company shall use its commercially reasonable efforts
to amend the Second Amended and Restated Registration Rights Agreement of the Company dated as of September 25, 2003 (as the same may be amended from time to time, the “Registration Rights Agreement”) to include the Warrant Shares
in the definition of Warrant Units thereunder. In the event that the Company is not successful in effecting such amendment within ninety (90) days following the date hereof, then within one hundred and twenty (120) days following the date 

  

 2 

 
hereof, the Company shall enter into a new registration rights agreement with respect to the Warrant Shares with the holders of Warrants issued pursuant to
or in connection with the Third Lien Credit Agreement on terms substantially similar to the Registration Rights Agreement (the “New RRA”). The Holder, once he or it executes a joinder to the Registration Rights Agreement or the New
RRA, as applicable, shall be entitled to registration rights in respect of the Warrant Shares pursuant to the terms and conditions of that certain Registration Rights Agreement or the New RRA, as applicable 
  
 3. Duration and Exercise of Warrants. 
  
 (a) This Warrant shall be exercisable by the registered Holder on any
business day before 5:00 P.M. Eastern time, and from time to time from and after the date hereof and through and including April     , 2015 (the “Expiration Date”). At 5:00 P.M., Eastern time on the
Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. Prior to the Expiration Date, the Company may not call or otherwise redeem this Warrant without the prior written consent of the
Holder. 
  
 (b) Upon surrender of this Warrant, with the Form of
Election to Purchase attached hereto and a joinder to the Stockholders Agreement as required by Section 2(f) above each duly completed and signed, to the Company at its address for notice set forth in Section 10 and upon payment of the Exercise
Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder, in the manner provided hereunder, all as specified by the Holder in the Form of Election to Purchase, the Company shall promptly (but in no event later
than five (5) business days after the Date of Exercise (as defined herein)) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in such name or names as the Holder may designate, a certificate for the
Warrant Shares issuable upon such exercise, free of restrictive legends except (i) either in the event that a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling stockholder thereunder is not then
effective or the Warrant Shares are not freely transferable without volume restrictions pursuant to Rule 144(k) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), (ii) if this Warrant shall have been
issued pursuant to a written agreement between the original Holder and the Company, as required by such agreement or (iii) as provided in the Stockholders Agreement or the Registration Rights Agreement or New RRA, as applicable. Any person so
designated by the Holder to receive Warrant Shares shall be deemed to have become the holder of record of such Warrant Shares as of the Date of Exercise of this Warrant. 
  
 (c) A “Date of Exercise” means the date on which the Company shall have received (i) this Warrant (or any
New Warrant, as applicable) with the Form of Election to Purchase attached hereto (or attached to such New Warrant) appropriately completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares so indicated by the
Holder hereof to be purchased. 
  
 (d) This Warrant shall be
exercisable, either in its entirety or, from time to time, for a portion of the number of Warrant Shares representing not less than 10% of the original Warrant Shares or such lesser amount as is then remaining available for exercise. If less than
all of the Warrant Shares which may be purchased under this Warrant are purchased at any time, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for
which no exercise has been evidenced by this Warrant. 
  

 3 

 4. Payment of Taxes. The Company will pay all documentary stamp taxes attributable to the issuance
of Warrant Shares upon the exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. 
  
 5. Replacement of Warrant. If this Warrant is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction and indemnity, if requested, satisfactory to it. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable charges as the Company may prescribe. 
  
 6.
Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other actual or contingent purchase rights of persons
other than the Holder (taking into account the adjustments and restrictions of Section 7). The Company covenants that all Warrant Shares that shall be so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price
in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. 
  
 7. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time
to time as set forth in this Section 7. Upon each such adjustment of the Exercise Price pursuant to this Section 7, the Holder shall thereafter prior to the Expiration Date be entitled to purchase, at the Exercise Price resulting from such
adjustment, the number of Warrant Shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such adjustment and
dividing the product thereof by the Exercise Price resulting from such adjustment. 
  
 (a) If the Company, at any time while this Warrant is outstanding, (i) shall pay a stock dividend (except scheduled dividends paid on preferred stock which contain a stated dividend rate) or otherwise make a
distribution or distributions on shares of its Common Stock or on any other class of capital stock payable in shares of Common Stock, (ii) subdivide outstanding shares of Common Stock into a larger number of shares, or (iii) combine outstanding
shares of Common Stock into a smaller number of shares, then the Exercise Price shall be multiplied by a fraction, of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event
and of which the denominator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding 

  

 4 

 
after such event. Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination of stockholders
entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination, and shall apply to successive subdivisions and combinations. 
  
 (b) In case of any reclassification of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is converted into other securities, cash or property, then the Holder shall have the right thereafter to exercise this Warrant only into the shares of stock and other securities and property
receivable upon or deemed to be held by holders of Common Stock following such reclassification or share exchange, and the Holder shall be entitled upon such event to receive such amount of securities or property equal to the amount of Warrant
Shares such Holder would have been entitled to had such Holder exercised this Warrant immediately prior to such reclassification or share exchange. The terms of any such reclassification or share exchange shall include such terms so as to continue
to give to the Holder the right to receive the securities or property set forth in this Section 7(b) upon any exercise following any such reclassification or share exchange. 
  
 (c) If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not
to the Holder of this Warrant) evidences of its indebtedness or assets (including cash) or rights or warrants to subscribe for or purchase any security (excluding those referred to in Sections 7(a), (b) and (d)), then in each such case the Exercise
Price shall be determined by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction the numerator of which shall be the Exercise Price
on such record date less the then fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of Common Stock as determined by the Board of Directors of the
Company in good faith and the denominator of which shall be the Exercise Price determined as of the record date mentioned above. 
  
 (d) If the Company or any subsidiary thereof, as applicable with respect to Common Stock Equivalents (as defined below), at any time while this Warrant is
outstanding, shall issue shares of Common Stock or rights, warrants, options or other securities or debt that is convertible into or exchangeable for shares of Common Stock (“Common Stock Equivalents”), to any Person (other than the
Holder of this Warrant), entitling such Person to acquire shares of Common Stock at a price per share less than the Exercise Price (if the holder of the Common Stock or Common Stock Equivalent so issued shall at any time, whether by operation of
purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights issued in connection with such issuance, be entitled to receive shares of Common Stock at a price less
than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price), then the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to the issuance of such Common Stock or such Common Stock Equivalents plus the number of shares of Common Stock which the offering price for such shares of Common Stock or Common Stock Equivalents would purchase at the Exercise
Price, and the denominator of which shall be the sum of the number of shares of Common Stock outstanding immediately prior to such issuance plus the number of shares of Common Stock so issued or issuable, provided that for purposes hereof,
all shares of Common Stock that are 

  

 5 

 
issuable upon conversion, exercise or exchange of Common Stock Equivalents shall be deemed outstanding immediately after the issuance of such Common Stock
Equivalents. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. However, upon the expiration of any Common Stock Equivalents the issuance of which resulted in an adjustment in the Exercise Price pursuant
to this Section, if any such Common Stock Equivalents shall expire and shall not have been exercised, the Exercise Price shall immediately upon such expiration be recomputed and effective immediately upon such expiration be increased to the price
which it would have been (but reflecting any other adjustments in the Exercise Price made pursuant to the provisions of this Section after the issuance of such Common Stock Equivalents) had the adjustment of the Exercise Price made upon the issuance
of such Common Stock Equivalents been made on the basis of offering for subscription or purchase only that number of shares of the Common Stock actually purchased upon the exercise of such Common Stock Equivalents actually exercised. The foregoing
shall not apply to any (i) issuances of securities as consideration in a merger, consolidation or acquisition of assets, or in connection with any strategic partnership or joint venture, or as consideration for the acquisition of a business,
product or license by the Company, (ii) the issuance of securities upon the exercise or conversion of the Company’s options, warrants or other convertible securities outstanding as of the date hereof, or (iii) the grant of options or warrants,
or the issuance of additional securities, under any duly authorized Company stock option, restricted stock plan or stock purchase plan for the benefit of the Company’s employees. 
  
 (e) In case of any (1) merger or consolidation of the Company with or into another Person, or (2) sale by the Company of
more than fifty percent 50% of the assets of the Company (based upon their then fair market value) in one or a series of related transactions, the Holder shall have the right at all times from and after the date of such merger, sale or
consolidation, as the case may be, to and including the Expiration Date, to exercise this Warrant for the shares of stock and other securities, cash and property receivable upon or deemed to be held by holders of Common Stock immediately following
such merger, consolidation or sale, and the Holder shall be entitled upon such event or series of related events to receive such amount of securities, cash and property as the Common Stock for which this Warrant could have been exercised immediately
prior to such merger, consolidation or sales would have been entitled. The terms of any such merger, sale or consolidation shall include such terms so as to continue to give the Holder the right to receive the securities, cash and property set forth
in this Section upon any conversion or redemption following such event. This provision shall similarly apply to successive such events. 
  
 (f) For the purposes of this Section 7, the following clauses shall also be applicable: 
  
 (i) Record Date. In case the Company shall take a record of the holders of its Common Stock for the purpose of
entitling them (A) to receive a dividend or other distribution payable in Common Stock or in securities convertible or exchangeable into shares of Common Stock, or (B) to subscribe for or purchase Common Stock or securities convertible or
exchangeable into shares of Common Stock, then such record date shall be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other
distribution or the date of the granting of such right of subscription or purchase, as the case may be. 
  

 6 

 (ii) Treasury Shares. The number of shares of Common Stock outstanding at any given time shall
not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock. 
  
 (g) All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case
may be. 
  
 (h) The Holder shall promptly mail or cause to be
mailed to the Company, a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment. Such adjustment shall become effective immediately after the record date mentioned
above. 
  
 (i) If: 
  

	 	(i)	the Company shall declare a dividend (or any other distribution) on its Common Stock; or 

  

	 	(ii)	the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock; or 

  

	 	(iii)	the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any
rights; or 

  

	 	(iv)	the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property; or 

  

	 	(v)	the Company shall authorize the voluntary dissolution, liquidation or winding up of the affairs of the Company, 

  
 then the Company shall cause to be mailed to the Holder at its last address as it shall
appear upon the Warrant Register, at least twenty (20) calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange
their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer, share exchange, dissolution, liquidation or winding up; provided, however, that the
failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. 
  

 7 

 8. Payment of Exercise Price. The Holder shall pay the Exercise Price in one of the following
manners: 
  
 (a) Cash Exercise. The holder may deliver
immediately available funds; or 
  
 (b) Cashless Exercise.

  
 (i) In lieu of exercising this Warrant in the manner
provided above in Section 1(a), the Holder may elect to receive Warrant Shares equal to the value of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company, together with
notice of such election, in which event the Company shall issue to such Holder a number of shares of Warrant Shares computed using the following formula: 
  

					
	X =	  	Y (A - B)	  	 
	 	  	A	  	 

  
 Where:

  

	 	X =	The number of Warrant Shares to be issued to the Holder. 

  

	 	Y =	The number of Warrant Shares purchasable (or to be purchased) under this Warrant (at the date of such calculation). 

  

	 	A =	The fair market value of one Warrant Share (at the date of such calculation). 

  

	 	B =	The Purchase Price (as adjusted to the date of such calculation). 

  
 (ii) For purposes of this Section 1(c), the “fair market value” of a Warrant Share on the date of calculation shall mean with
respect to such Warrant Share: 
  
 (A) if the
exercise of this Warrant is in connection with an initial public offering of any Common Stock or equivalent equity securities of the Company (which, for the purposes of this Section 1(c)(ii), shall be deemed to include any successor entity
thereto), and if the Company’s Registration Statement relating to such public offering has been declared effective by the Securities and Exchange Commission, then the fair market value of a Warrant Share shall be the initial “Price to
Public” for such share of Common Stock or equivalent equity securities (expressed on a per share of Common Stock basis) specified in the final prospectus with respect to the offering; 
  
 (B) if this Warrant is exercised after, and not in
connection with, the Company’s initial public offering, and if the Common Stock or equivalent equity securities of the Company are traded on a securities exchange or the Nasdaq Stock Market or actively traded over-the-counter: 
  
 (1) if the Common Stock or equivalent equity securities of
the Company are traded on a securities exchange or the Nasdaq Stock Market, the fair market value per share of Common Stock or equivalent equity security 
  

 8 

 shall be deemed to be the product of (x) the average of the closing prices of such Common Stock or
equivalent equity securities over a thirty (30) day period ending three days before date of calculation and (y) the number of shares of Common Stock or equivalent equity securities to which each Warrant Shares relates on such date; or 
  
 (2) if the Common Stock or equivalent equity securities of
the Company are actively traded over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid or sales price (whichever is applicable) of such Common Stock or equivalent equity securities over the
thirty (30) day period ending three days before the date of calculation, and (y) the number of shares of Common Stock or equivalent equity securities to which each Warrant Share relates on such date; or 
  
 (C) if neither (A) nor (B) is applicable, the fair market value per Warrant
Share shall be the highest price per share of Common Stock or equivalent equity security which the Company could obtain on the date of calculation from a willing buyer (not a current employee, stockholder or director) for Common Stock or equivalent
equity securities sold by the Company, as determined in good faith by the Board of Directors (or committee thereof) of the Company, unless the Company is at such time subject to an acquisition as described in Section 6(b) below, in which case
the fair market value per Warrant Share shall be deemed to be the value to be received by the holders of the Common Stock or equivalent equity securities for each share of Common Stock or equivalent equity security pursuant to such acquisition.

  
 9. Fractional Shares. The Company shall not be required
to issue or cause to be issued fractional Warrant Shares on the exercise of this Warrant. The number of full Warrant Shares which shall be issuable upon the exercise of this Warrant shall be computed on the basis of the aggregate number of Warrant
Shares purchasable on exercise of this Warrant so presented. If any fraction of a Warrant Share would, except for the provisions of this Section, be issuable on the exercise of this Warrant, the Company shall pay an amount in cash equal to the
Exercise Price multiplied by such fraction. 
  
 10.
Notices. Any and all notices or other communications or deliveries hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile telephone number specified in this Section prior to 6:00 p.m. (Eastern time) on a business day, (ii) the business day after the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile telephone number specified in this Section later than 5:00 p.m. (Eastern time) on any date and earlier than 11:59 p.m. (Eastern time) on such date, (iii) the business day following the date of mailing, if sent by nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be: 
  

			
	 If to the Company:
	  	 Reliant Pharmaceuticals, Inc.

	 	  	 110 Allen Road

	 	  	 Liberty Corner, NJ 07938

	 	  	 Facsimile No.: (908) 542-9406

	 	  	 Attn: Chief Financial Officer

  

 9 

			
	 With copies to:
	  	 Latham & Watkins LLP

	 	  	 5800 Sears Tower

	 	  	 Chicago, IL 60606

	 	  	 Facsimile No.: (312) 993-9767

	 	  	 Attn: Michael A. Pucker

		
	 If to a Purchaser:
	  	 At the address set forth in the Warrant Register.

  
 11. Warrant
Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any
corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services
business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder
at the Holder’s last address as shown on the Warrant Register. 
  
 12. Miscellaneous. 
  
 (a) This Warrant shall be
binding on and inure to the benefit of the parties hereto and their respective successors and assigns. This Warrant may be amended or waived only in writing signed by the Company and the Holder and their successors and assigns. 
  
 (b) Subject to Section 12(a), above, nothing in this Warrant shall be
construed to give to any person or corporation other than the Company and the Holder any legal or equitable right, remedy or cause under this Warrant. This Warrant shall inure to the sole and exclusive benefit of the Company and the Holder.

  
 (c) This Warrant and all questions concerning the
construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof.

  
 (d) The headings herein are for convenience only, do not
constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. 
  
 (e) In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute
therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; 
 SIGNATURE PAGE FOLLOWS] 

 

 10 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its duly authorized
officer as of the date first indicated above. 
  

									
	 	 	 	 	 	 	RELIANT PHARMACEUTICALS, INC.
					
	 	 	 	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 
	 AGREED TO AND ACKNOWLEDGED:
	 	 	 	 	 	 
				
	[NAME OF HOLDER]	 	 	 	 	 	 
					
	 By:
	 	  

	 	 	 	 	 	 
	 Name:
	 	 	 	 	 	 	 	 
	 Title:
	 	 	 	 	 	 	 	 

 FORM OF ELECTION TO PURCHASE 
  
 (To be executed by the Holder along with a joinder to the Stockholders’ Agreement (if any) to exercise the right to purchase shares of
Common Stock under the foregoing Warrant) 
  
 To Reliant Pharmaceuticals, Inc.:

  
 The undersigned hereby irrevocably elects to purchase
                     shares of common stock, $.01 par value per share, of Reliant Pharmaceuticals, Inc. (the “Common Stock”) and
encloses herewith $             in cash, certified or official bank check or checks, which sum represents the aggregate Exercise Price (as defined in the Warrant) for the number of
shares of Common Stock to which this Form of Election to Purchase relates, together with any applicable taxes payable by the undersigned pursuant to the Warrant. 
  
 The Exercise Price applicable to the purchase hereunder equals
$            . 
  
 The Holder hereby represents and warrants to the Company that it is an accredited investor under Rule 501(a) promulgated under the Securities Act of 1933, as amended. 
  
 The undersigned requests that certificates for the shares of Common Stock
issuable upon this exercise be issued in the name of 
  

					
	 	 	 	  	 PLEASE INSERT SOCIAL SECURITY OR
 TAX IDENTIFICATION NUMBER

	 	 	 	  	  

			
	  

	 	 	  	 
	 (Please print name and address)
	 	 	  	 
	  

	 	 	  	 
	  

	 	 	  	 

  
 If the number of
shares of Common Stock issuable upon this exercise shall not be all of the shares of Common Stock which the undersigned is entitled to purchase in accordance with the enclosed Warrant, the undersigned requests that a New Warrant (as defined in the
Warrant) evidencing the right to purchase the shares of Common Stock not issuable pursuant to the exercise evidenced hereby be issued in the name of and delivered to: 
  

					
	  

	 	 	 	 
	 (Please print name and address)
	 	 	 	 
	  

	 	 	 	 
	  

	 	 	 	 
			
	 Dated:
                    
	 	 	 	 
	 	 	 Name of Holder:

			
	 	 	 (Print)
	 	  

			
	 	 	 (By:)
	 	  

	 	 	 (Name:)
	 	  

	 	 	 (Title:)
	 	  

	 	 	 (Signature must conform in all respects to name of holder as specified on the face of the Warrant)

  

 FORM OF ASSIGNMENT 
  
 [To be completed and signed only upon transfer of Warrant] 
  
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
                                        
                 the right represented by the within Warrant to purchase
                     shares of Common Stock of Reliant Pharmaceuticals, Inc. to which the within Warrant relates and appoints
                                     attorney to transfer said
right on the books of Reliant Pharmaceuticals, Inc. with full power of substitution in the premises. 
  

			
	 Dated:                    ,
            
	  	 
	 	  	  
  

	 	  	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)
		
	 	  	  

	 	  	 Address of Transferee

		
	 	  	  

		
	 	  	  

		
	 In the presence of:Reliant Pharmaceuticals, Inc. 2004 Equity Incentive Plan

 Exhibit 10.1 
  
 RELIANT PHARMACEUTICALS, INC. 
 2004 EQUITY INCENTIVE PLAN 
  
 ARTICLE 1 
 PURPOSE 
  
 The purpose of the Reliant Pharmaceuticals, Inc. 2004 Equity Incentive Plan (the “Plan”) is to promote the success and enhance the value of Reliant
Pharmaceuticals, Inc. (the “Company”) by offering to selected Employees, Consultants and Independent Directors of the Company or any of its Subsidiaries the ability to acquire equity interests in the Company, thereby helping to
attract, retain and reward such persons, and strengthen the alignment of interests between such persons and the Company. 
  
 ARTICLE 2 
 DEFINITIONS AND
CONSTRUCTION 
  
 2.1 DEFINITIONS. The following
words and phrases shall have the following meanings: 
  
 (a)
“Award” means an Option, a Restricted Stock award, a Performance Share award, a Dividend Equivalents award, a Stock Payment award, a Deferred Stock award, or a Performance-Based Award granted to a Participant pursuant to the Plan.

  
 (b) “Award Agreement” means any written
agreement, contract, or other instrument or document evidencing an Award. 
  
 (c) “Board” means the Board of Directors of the Company. 
  
 (d) “Cause” means a termination by the Company or any Subsidiary of the Participant’s relationship with the Company or any
Subsidiary due to (i) the commission by the Participant of an act of fraud against the Company or any Subsidiary or any affiliate thereof or embezzlement, (ii) a breach of one or more of the following duties to the Company or any Subsidiary: (A) the
duty of loyalty, (B) the duty not to take willful actions which would reasonably be viewed by the Company or any Subsidiary as placing the Participant’s interest in a position adverse to the interest of the Company or any Subsidiary, (C) the
duty not to engage in self-dealing with respect to the Company’s or any Subsidiary’s assets, properties or business opportunities, except as approved in writing by the Board, (D) the duty of honesty or (E) any other fiduciary duty which
the Participant owes to the Company or any Subsidiary, (iii) a conviction of the Participant (or a plea of nolo contendere in lieu thereof) for (A) a felony or (B) a crime involving fraud, dishonesty or moral turpitude, (iv) intentional
misconduct with respect to his duties to the Company or any Subsidiary, including, but not limited to, knowing and intentional violation by the Participant of written policies of the Company or any Subsidiary, including policies regarding
confidential information and non-competition, or specific directions of the Board or superior officers of the Company or any Subsidiary, which policies or directives are neither illegal (or do not involve illegal conduct) nor do they require the
Participant to violate reasonable business ethical standards, or (v) the failure of the Participant, after written notice from the Company or any Subsidiary, to render services to the Company or any Subsidiary in accordance with his employment or
other relationship with the Company or any Subsidiary, which failure is not cured within 10 days of receipt of such notice. 

 (e) “Change of Control” means and includes each of the following: 
  
 (1) the acquisition, directly or indirectly, by any “person” or
“group” (as those terms are defined in Sections 3(a)(9), 13(d) and 14(d) of the Exchange Act and the rules thereunder) of “beneficial ownership” (as determined pursuant to Rule 13d-3 under the Exchange Act) of securities entitled
to vote generally in the election of directors (“voting securities”) of the Company that represent 50% or more of the combined voting power of the Company’s then outstanding voting securities, other than: 
  
 (A) an acquisition by a trustee or other fiduciary holding securities under
any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company or by any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the
Company, or 
  
 (B) an acquisition of voting securities by the
Company or a corporation owned, directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the stock of the Company, or 
  
 (C) an acquisition of voting securities pursuant to a transaction described in clause (2) below that would not be a Change
of Control under clause (2); 
  
 Notwithstanding the foregoing,
neither of the following events shall constitute an “acquisition” by any person or group for purposes of this subsection (e): an acquisition of the Company’s securities by the Company which causes the Company’s voting securities
beneficially owned by a person or group to represent 50% or more of the combined voting power of the Company’s then outstanding voting securities; provided, however, that if a person or group shall become the beneficial owner of 50% or
more of the combined voting power of the Company’s then outstanding voting securities by reason of share acquisitions by the Company as described above and shall, after such share acquisitions by the Company, become the beneficial owner of any
additional voting securities of the Company, then such acquisition shall constitute a Change of Control; or 
  
 (2) the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of
(x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets or (z) the acquisition of assets or stock of another entity, in each case other than a
transaction: 
  
 (A) which results in the Company’s voting
securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or
indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or
indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and 
  

 2 

 (B) after which no person or group beneficially owns voting securities representing 50% or more of the
combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this clause (B) as beneficially owning 50% or more of combined voting power of the Successor Entity solely as a result
of the voting power held in the Company prior to the consummation of the transaction; or 
  
 (3) the Company’s stockholders approve a liquidation or dissolution of the Company other than in connection with a corporate restructuring transaction. 
  
 The Committee shall have full and final authority, which shall be exercised
in its discretion, to determine conclusively whether a Change of Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change of Control and any incidental matters relating thereto. 

 
 (f) “Code” means the Internal Revenue Code of 1986, as
amended. 
  
 (g) “Committee” means the committee
of the Board described in Article 11. 
  
 (h)
“Consultant” means any consultant or adviser if: (i) the consultant or adviser renders bona fide services to the Company or any Subsidiary; (ii) the services rendered by the consultant or adviser are not in connection with the offer
or sale of securities in a capital-raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities; and (iii) the consultant or adviser is a natural person. 
  
 (i) “Covered Employee” means an Employee who is, or could
be, a “covered employee” within the meaning of Section 162(m) of the Code. 
  
 (j) “Deferred Stock” means a right to receive a specified number of shares of Stock during specified time periods pursuant to Article 7. 
  
 (k) “Disability” means, for purposes of this Plan, that the Participant qualifies or would qualify if he
were a participant to receive long-term disability payments under the Company’s long-term disability insurance program, as it may be amended from time to time. 
  
 (l) “Dividend Equivalents” means a right granted to a Participant pursuant to Article 7 to receive the
equivalent value (in cash or Stock) of dividends paid on Stock. 
  
 (m) “Employee” means any officer or other employee (as defined in accordance with Section 3401(c) of the Code) of the Company or any Subsidiary. 
  
 (n) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  

 3 

 (o) “Fair Market Value” means, as of any given date, the fair market value of a share of
Stock on a particular date determined as follows: 
  
 (1) If the Common Stock is listed on any established stock exchange or a national market system, including, without limitation, the Nasdaq National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its Fair Market Value shall
be the closing sales price for a share of such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system for the last market trading day prior to the time of determination, as reported in The Wall Street
Journal or such other source as the Committee deems reliable; 
  
 (2) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, its Fair Market Value shall be the mean between the high bid and low asked prices for a share of the
Common Stock on the last market trading day prior to the day of determination; or 
  
 (3) In the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the
Committee which determination shall be final and binding. 
  
 (p)
“Incentive Stock Option” means an Option that is intended to meet the requirements of Section 422 of the Code or any successor provision thereto. 
  
 (q) “Independent Director” means a Director who is not an Employee of the Company. 
  
 (r) “Non-Employee Director” means a member of the Board who
qualifies as a “Non-Employee Director” as defined in Rule 16b-3(b)(3) of the Exchange Act, or any successor definition adopted by the Board. 
  
 (s) “Non-Qualified Stock Option” means an Option that is not intended to be an Incentive Stock Option. 
  
 (t) “Option” means a right granted to a Participant pursuant
to Article 5 of the Plan to purchase a specified number of shares of Stock at a specified price during specified time periods. An Option may be either an Incentive Stock Option or a Non-Qualified Stock Option. 
  
 (u) “Participant” means a person who, as a Independent
Director, Consultant or Employee, has been granted an Award pursuant to the Plan. 
  
 (v) “Performance-Based Award” means an Award granted to selected Covered Employees pursuant to Articles 6 and 7, but which is subject to the terms and conditions set forth in Article 8. All
Performance-Based Awards are intended to qualify as Qualified Performance-Based Compensation. 
  
 (w) “Performance Criteria” means the criteria that the Committee selects for purposes of establishing the Performance Goal or Performance Goals for a Participant for a Performance Period. The
Performance Criteria that will be used to establish Performance Goals are limited to the following: net earnings (either before or after interest, taxes, depreciation and amortization), sales or revenue, operating earnings, operating cash flow,
return on net assets, return on stockholders’ equity, return on assets, return on capital, stockholder returns, gross or 
  

 4 

 net profit margin, earnings per share, price per share of Stock, market share, product acquisitions, product development,
achievement of special project objectives, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group. The Committee shall, within the time prescribed by Section 162(m)
of the Code, define in an objective fashion the manner of calculating the Performance Criteria it selects to use for such Performance Period for such Participant. 
  
 (x) “Performance Goals” means, for a Performance Period, the goals established in writing by the Committee
for the Performance Period based upon the Performance Criteria. Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a
division, business unit, or an individual. The Committee, in its discretion, may, within the time prescribed by Section 162(m) of the Code, adjust or modify the calculation of Performance Goals for such Performance Period in order to prevent the
dilution or enlargement of the rights of Participants (i) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event, or development, or (ii) in recognition of, or in anticipation of, any other unusual or
nonrecurring events affecting the Company, or the financial statements of the Company, or in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business conditions. 
  
 (y) “Performance Period” means the one or more periods of
time, which may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a
Performance-Based Award. 
  
 (z) “Performance
Share” means a right granted to a Participant pursuant to Article 7, to receive cash, Stock, or other Awards, the payment of which is contingent upon achieving certain performance goals established by the Committee. 
  
 (aa) “Plan” means this Reliant Pharmaceuticals, Inc. 2004
Equity Incentive Plan, as it may be amended from time to time. 
  
 (bb) “Public Trading Date” means the first date upon which the Stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance
as a national market security on an interdealer quotation system. 
  
 (cc) “Qualified Performance-Based Compensation” means any compensation that is intended to qualify as “qualified performance-based compensation” as described in Section 162(m)(4)(C) of the Code. 
  
 (dd) “Restricted Stock” means Stock awarded to a Participant
pursuant to Article 6 that is subject to certain restrictions and to risk of forfeiture. 
  
 (ee) “Stock” means the common stock of the Company, par value $0.01 per share, and such other securities of the Company that may be substituted for Stock pursuant to Article 10. 
  

 5 

 (ff) “Stock Payment” means (a) a payment in the form of shares of Stock, or (b) an
option or other right to purchase shares of Stock, as part of any bonus, deferred compensation or other arrangement, made in lieu of all or any portion of the compensation, granted pursuant to Article 7. 
  
 (gg) “Subsidiary” means any corporation or other entity of
which a majority of the outstanding voting stock or voting power is beneficially owned directly or indirectly by the Company. 
  
 ARTICLE 3 
 SHARES SUBJECT TO THE PLAN

  
 3.1 NUMBER OF SHARES. 
  
 (a) Subject to Article 11, the aggregate number of shares of Stock which may
be issued or transferred pursuant to Awards under the Plan shall be the sum of (i) 1,343,600 shares of Stock; plus (ii) any shares of Stock which would again become available for issuance under the Company’s Equity Incentive Plan (formerly
known as the Reliant Pharmaceuticals, LLC Equity Incentive Plan) upon forfeiture of options or restricted stock previously granted thereunder. The payment of Dividend Equivalents in conjunction with any outstanding Awards shall not be counted
against the shares available for issuance under the Plan. 
  
 (b)
To the extent that an Award terminates, expires, or lapses for any reason, any shares of Stock subject to the Award shall again be available for the grant of an Award pursuant to the Plan. Additionally, any shares of Stock tendered or withheld to
satisfy the grant or exercise price or tax withholding obligation pursuant to any Award shall again be available for the grant of an Award pursuant to the Plan. To the extent permitted by applicable law or any exchange rule, shares of Stock issued
in assumption of, or in substitution for, any outstanding awards of any entity acquired in any form of combination by the Company or any Subsidiary shall not be counted against shares of Stock available for grant pursuant to this Plan. 

 
 3.2 STOCK DISTRIBUTED. Any Stock distributed pursuant to an
Award may consist, in whole or in part, of authorized and unissued Stock, treasury Stock or Stock purchased on the open market. 
  
 3.3 LIMITATION ON NUMBER OF SHARES SUBJECT TO AWARDS. Notwithstanding any provision in the Plan to the contrary, and subject to Article 11
following the Public Trading Date and after the earliest date pursuant to which Section 162(m) of the Code and the rules and regulations promulgated thereunder become applicable to the Plan, the maximum number of shares of Stock with respect to one
or more Awards that are intended to be Qualified Performance-Based Compensation that may be granted to any one Participant shall not exceed 1,000,000 shares of Stock in any twelve-month period. 
  

 6 

 ARTICLE 4 
 ELIGIBILITY AND PARTICIPATION 
  
 4.1 ELIGIBILITY. 
  
 (a) GENERAL. Persons
eligible to participate in this Plan include Employees, Consultants and Independent Directors, as determined by the Committee. 
  
 (b) FOREIGN PARTICIPANTS. In order to assure the viability of Awards granted to Participants employed in foreign countries, the Committee may provide for
such special terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy, or custom. Moreover, the Committee may approve such supplements to, or amendments, restatements, or alternative versions of, the Plan
as it may consider necessary or appropriate for such purposes without thereby affecting the terms of the Plan as in effect for any other purpose; provided, however, that no such supplements, amendments, restatements, or alternative versions
shall increase the share limitations contained in Sections 3.1 and 3.3 of the Plan. 
  
 4.2 ACTUAL PARTICIPATION. Subject to the provisions of the Plan, the Committee may, from time to time, select from among all eligible individuals, those to whom Awards shall be granted and shall
determine the nature and amount of each Award. No individual shall have any right to be granted an Award pursuant to this Plan. 
  
 ARTICLE 5 
 STOCK OPTIONS

  
 5.1 GENERAL. The Committee is authorized to
grant Options to Participants on the following terms and conditions: 
  
 (a) EXERCISE PRICE. The exercise price per share of Stock subject to an Option shall be determined by the Committee and set forth in the Award Agreement; provided that the exercise price for any Option shall not be less than 100% of
Fair Market Value on the date of grant. 
  
 (b) TIME AND
CONDITIONS OF EXERCISE. The Committee shall determine the time or times at which an Option may be exercised in whole or in part, provided that the term of any Option granted under the Plan shall not exceed ten years. The Committee shall also
determine the performance or other conditions, if any, that must be satisfied before all or part of an Option may be exercised. Unless otherwise provided in an Award Agreement, an Option will lapse immediately if a Participant’s employment is
terminated for Cause. 
  
 (c) PAYMENT. The Committee shall
determine the methods by which the exercise price of an Option may be paid, the form of payment, including, without limitation, cash, promissory note bearing interest at no less than such rate as shall then preclude the imputation of interest under
the Code, shares of Stock held for longer than six months having a Fair Market Value on the date of delivery equal to the aggregate exercise price of the Option or exercised portion thereof, or other property acceptable to the Committee (including
through the delivery of a notice that the Participant has placed a market sell order with a broker with respect 
  

 7 

 to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient
portion of the net proceeds of the sale to the Company in satisfaction of the Option exercise price, provided that payment of such proceeds is then made to the Company upon settlement of such sale), and the methods by which shares of Stock
shall be delivered or deemed to be delivered to Participants. Notwithstanding any other provision of the Plan to the contrary, no Participant who is a member of the Board or an “executive officer” of the Company within the meaning of
Section 13(k) of the Exchange Act shall be permitted to pay the exercise price of an Option in any method which would violate Section 13(k) of the Exchange Act. 
  

(d) EVIDENCE OF GRANT. All Options shall be evidenced by a written Award Agreement between the Company and the Participant. The Award Agreement shall
include such additional provisions as may be specified by the Committee. 
  
 5.2 INCENTIVE STOCK OPTIONS. Incentive Stock Options shall be granted only to Employees and the terms of any Incentive Stock Options granted pursuant to the Plan must comply with the following additional
provisions of this Section 5.2: 
  
 (a) EXERCISE PRICE. The
exercise price per share of Stock shall be set by the Committee, provided that the exercise price for any Incentive Stock Option shall not be less than 100% of the Fair Market Value on the date of grant. 
  
 (b) EXPIRATION OF OPTION. An Incentive Stock Option may not be exercised to
any extent by anyone after the first to occur of the following events:: 
  
 (1) Ten years from the date it is granted, unless an earlier time is set in the Award Agreement. 
  
 (2) The Participant’s termination of employment for Cause or termination of employment or service for any other reason other than
the Participant’s death or Disability, unless otherwise provided in the Award Agreement. 
  
 (3) One year after the date of the Participant’s termination of employment or service on account of Disability or death. Upon the
Participant’s Disability or death, any Incentive Stock Options exercisable at the Participant’s Disability or death may be exercised by the Participant’s legal representative or representatives, by the person or persons entitled to do
so pursuant to the Participant’s last will and testament, or, if the Participant fails to make testamentary disposition of such Incentive Stock Option or dies intestate, by the person or persons entitled to receive the Incentive Stock Option
pursuant to the applicable laws of descent and distribution. 
  
 (c) INDIVIDUAL DOLLAR LIMITATION. The aggregate Fair Market Value (determined as of the time the Option is granted) of all shares of Stock with respect to which Incentive Stock Options are first exercisable by a Participant in any calendar
year may not exceed $100,000.00 or such other limitation as imposed by Section 422(d) of the Code, or any successor provision. To the extent that Incentive Stock Options are first exercisable by a Participant in excess of such limitation, the excess
shall be considered Non-Qualified Stock Options. 
  

 8 

 (d) TEN PERCENT OWNERS. An Incentive Stock Option shall be granted to any individual who, at the date of
grant, owns stock possessing more than ten percent of the total combined voting power of all classes of Stock of the Company only if such Option is granted at a price that is not less than 110% of Fair Market Value on the date of grant and the
Option is exercisable for no more than five years from the date of grant. 
  
 (e) TRANSFER RESTRICTION. The Participant shall give the Company prompt notice of any disposition of shares of Stock acquired by exercise of an Incentive Stock Option within (2) two years from the date of grant of
such Incentive Stock Option, or (1) one year after the transfer of such shares of Stock to the Participant. 
  
 (f) EXPIRATION OF INCENTIVE STOCK OPTIONS. No Award of an Incentive Stock Option may be made pursuant to this Plan after the tenth anniversary of the
Effective Date. 
  
 (g) RIGHT TO EXERCISE. During a
Participant’s lifetime, an Incentive Stock Option may be exercised only by the Participant.  
  
 ARTICLE 6 
 RESTRICTED STOCK AWARDS 
  
 6.1 GRANT OF RESTRICTED STOCK. The Committee is authorized to
make Awards of Restricted Stock to any Participant selected by the Committee in such amounts and subject to such terms and conditions as determined by the Committee. All Awards of Restricted Stock shall be evidenced by a written Restricted Stock
Award Agreement. 
  
 6.2 ISSUANCE AND RESTRICTIONS.
Restricted Stock shall be subject to such restrictions on transferability and other restrictions as the Committee may impose (including, without limitation, limitations on the right to vote Restricted Stock or the right to receive dividends on the
Restricted Stock). These restrictions may lapse separately or in combination at such times, pursuant to such circumstances, in such installments, or otherwise, as the Committee determines at the time of the grant of the Award or thereafter.

  
 6.3 FORFEITURE. Except as otherwise determined
by the Committee at the time of the grant of the Award or thereafter, upon termination of employment or service during the applicable restriction period, Restricted Stock that is at that time subject to restrictions shall be forfeited; provided,
however, that the Committee may provide in any Restricted Stock Award Agreement that restrictions or forfeiture conditions relating to Restricted Stock will be waived in whole or in part in the event of terminations resulting from specified
causes, and the Committee may in other cases waive in whole or in part restrictions or forfeiture conditions relating to Restricted Stock. 
  
 6.4 CERTIFICATES FOR RESTRICTED STOCK. Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Committee shall
determine. If certificates representing shares of Restricted Stock are registered in the name of the Participant, certificates must bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock,
and the Company may, at its discretion, retain physical possession of the certificate until such time as all applicable restrictions lapse. 
  

 9 

 ARTICLE 7 
 OTHER TYPES OF AWARDS 
  
 7.1 PERFORMANCE SHARE AWARDS. Any Participant selected by the Committee may be granted one or more Performance Share awards which may be denominated in a number of shares of Stock or in a dollar value of shares of Stock and
which may be linked to any one or more of the Performance Criteria or other specific performance criteria determined appropriate by the Committee, in each case on a specified date or dates or over any period or periods determined by the Committee.
In making such determinations, the Committee shall consider (among such other factors as it deems relevant in light of the specific type of award) the contributions, responsibilities and other compensation of the particular Participant. 

 
 7.2 DIVIDEND EQUIVALENTS. 
  
 (a) Any Participant selected by the Committee may be granted Dividend
Equivalents based on the dividends declared on the shares of Stock that are subject to any Award, to be credited as of dividend payment dates, during the period between the date the Award is granted and the date the Award is exercised, vests or
expires, as determined by the Committee. Such Dividend Equivalents shall be converted to cash or additional shares of Stock by such formula and at such time and subject to such limitations as may be determined by the Committee. 
  
 (b) Dividend Equivalents granted with respect to Options that are intended to
be Qualified Performance-Based Compensation shall be payable, with respect to pre-exercise periods, regardless of whether such Option is subsequently exercised. 
  

7.3 STOCK PAYMENTS. Any Participant selected by the Committee may receive Stock Payments in the manner determined from time to time by
the Committee. The number of shares shall be determined by the Committee and may be based upon the Performance Criteria or other specific performance criteria determined appropriate by the Committee, determined on the date such Stock Payment is made
or on any date thereafter. 
  
 7.4 DEFERRED STOCK.
Any Participant selected by the Committee may be granted an award of Deferred Stock in the manner determined from time to time by the Committee. The number of shares of Deferred Stock shall be determined by the Committee and may be linked to the
Performance Criteria or other specific performance criteria determined to be appropriate by the Committee, in each case on a specified date or dates or over any period or periods determined by the Committee. Stock underlying a Deferred Stock award
will not be issued until the Deferred Stock award has vested, pursuant to a vesting schedule or performance criteria set by the Committee. Unless otherwise provided by the Committee, a Participant awarded Deferred Stock shall have no rights as a
Company stockholder with respect to such Deferred Stock until such time as the Deferred Stock Award has vested and the Stock underlying the Deferred Stock Award has been issued. 
  
 7.5 TERM. The term of any Award of Performance Shares, Dividend Equivalents, Stock Payments or Deferred Stock
shall be set by the Committee in its discretion. 
  

 10 

 7.6 EXERCISE OR PURCHASE PRICE. The Committee may establish the exercise or purchase price
of any Award of Performance Shares, Deferred Stock or Stock Payments; provided, however, that such price shall not be less than the par value of a share of Stock, unless otherwise permitted by applicable state law. 
  
 7.7 EXERCISE UPON TERMINATION OF EMPLOYMENT OR SERVICE. An
Award of Performance Shares, Dividend Equivalents, Deferred Stock and Stock Payments shall only be exercisable or payable while the Participant is an Employee, Consultant or a member of the Board, as applicable; provided, however, that the Committee
in its sole and absolute discretion may provide that an Award of Performance Shares, Dividend Equivalents, Stock Payments or Deferred Stock may be exercised or paid subsequent to a termination of employment or service, as applicable, or following a
Change of Control of the Company, or because of the Participant’s retirement, death or disability, or otherwise; provided, however, that any such provision with respect to Performance Shares shall be subject to the requirements of Section
162(m) of the Code that apply to Qualified Performance-Based Compensation. 
  
 7.8 FORM OF PAYMENT. Payments with respect to any Awards granted under this Article 7 shall be made in cash, in Stock or a combination of both, as determined by the Committee. 
  
 7.9 AWARD AGREEMENT. All Awards under this Article 7 shall be
subject to such additional terms and conditions as determined by the Committee and shall be evidenced by a written Award Agreement. 
  
 ARTICLE 8 
 PERFORMANCE-BASED AWARDS

  
 8.1 PURPOSE. The purpose of this Article 8
is to provide the Committee the ability to qualify Awards other than Options and that are granted pursuant to Articles 6 and 7 as Qualified Performance-Based Compensation to the extent that Section 162(m) of the Code is applicable to the Company. If
the Committee, in its discretion, decides to grant a Performance-Based Award to a Covered Employee, the provisions of this Article 8 shall control over any contrary provision contained in Articles 6 or 7; provided, however, that the Committee
may in its discretion grant Awards to Covered Employees that are based on Performance Criteria or Performance Goals but that do not satisfy the requirements of this Article 8. 
  
 8.2 APPLICABILITY. This Article 8 shall apply only to those Covered Employees selected by the Committee to
receive Performance-Based Awards. The designation of a Covered Employee as a Participant for a Performance Period shall not in any manner entitle the Participant to receive an Award for the period. Moreover, designation of a Covered Employee as a
Participant for a particular Performance Period shall not require designation of such Covered Employee as a Participant in any subsequent Performance Period and designation of one Covered Employee as a Participant shall not require designation of
any other Covered Employees as a Participant in such period or in any other period. 
  
 8.3 PROCEDURES WITH RESPECT TO PERFORMANCE-BASED AWARDS. To the extent necessary to comply with the Qualified Performance-Based 
  

 11 

 Compensation requirements of Section 162(m)(4)(C) of the Code, with respect to any Award granted under Articles 6 and 7
which may be granted to one or more Covered Employees, no later than ninety (90) days following the commencement of any fiscal year in question or any other designated fiscal period or period of service (or such other time as may be required or
permitted by Section 162(m) of the Code), the Committee shall, in writing, (i) designate one or more Covered Employees, (ii) select the Performance Criteria applicable to the Performance Period, (iii) establish the Performance Goals, and amounts of
such Awards, as applicable, which may be earned for such Performance Period, and (iv) specify the relationship between Performance Criteria and the Performance Goals and the amounts of such Awards, as applicable, to be earned by each Covered
Employee for such Performance Period. Following the completion of each Performance Period, the Committee shall certify in writing whether the applicable Performance Goals have been achieved for such Performance Period. In determining the amount
earned by a Covered Employee, the Committee shall have the right to reduce or eliminate (but not to increase) the amount payable at a given level of performance to take into account additional factors that the Committee may deem relevant to the
assessment of individual or corporate performance for the Performance Period. 
  
 8.4 PAYMENT OF PERFORMANCE-BASED AWARDS. Unless otherwise provided in the applicable Award Agreement, a Participant must be employed by the Company or a Subsidiary on the day a Performance-Based Award
for such Performance Period is paid to the Participant. Furthermore, a Participant shall be eligible to receive payment pursuant to a Performance-Based Award for a Performance Period only if the Performance Goals for such period are achieved. In
determining the amount earned under a Performance-Based Award, the Committee may reduce or eliminate the amount of the Performance-Based Award earned for the Performance Period, if in its sole and absolute discretion, such reduction or elimination
is appropriate. 
  
 8.5 ADDITIONAL LIMITATIONS.
Notwithstanding any other provision of the Plan, any Award which is granted to a Covered Employee and is intended to constitute Qualified Performance-Based Compensation shall be subject to any additional limitations set forth in Section 162(m) of
the Code (including any amendment to Section 162(m) of the Code) or any regulations or rulings issued thereunder that are requirements for qualification as Qualified Performance-Based Compensation as described in Section 162(m)(4)(C) of the Code,
and the Plan shall be deemed amended to the extent necessary to conform to such requirements. 
  
 ARTICLE 9 
 PROVISIONS APPLICABLE TO AWARDS 
  
 9.1 STAND-ALONE AND TANDEM AWARDS. Awards granted pursuant to
the Plan may, in the discretion of the Committee, be granted either alone, in addition to, or in tandem with, any other Award granted pursuant to the Plan. Awards granted in addition to or in tandem with other Awards may be granted either at the
same time as or at a different time from the grant of such other Awards. 
  
 9.2 AWARD AGREEMENT. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award which may include the term of an Award, the
provisions applicable in the event the Participant’s 
  

 12 

 employment or service terminates, and the Company’s authority to unilaterally or bilaterally amend, modify, suspend,
cancel or rescind an Award. Prior to the Public Trading Date, the Committee in its discretion may provide that the Company may repurchase Stock acquired under any Award upon a Participant’s termination of employment, or service as a Consultant
or as a member of the Board; provided, however that any such repurchase right shall be set forth in the applicable Award Agreement or in another agreement referred to in such agreement. 
  
 9.3 EFFECT OF TERMINATION FOR CAUSE. Unless expressly provided
otherwise provided in an Award Agreement, a Participant’s Awards and all rights thereunder shall be forfeited immediately if a Participant’s employment is terminated for Cause 
  
 9.4 LIMITS ON TRANSFER. No right or interest of a Participant in any Award may be pledged, encumbered, or
hypothecated to or in favor of any party other than the Company or a Subsidiary, or shall be subject to any lien, obligation, or liability of such Participant to any other party other than the Company or a Subsidiary. Except as otherwise provided by
the Committee, no Award shall be assigned, transferred, or otherwise disposed of by a Participant other than by will or the laws of descent and distribution. The Committee by express provision in the Award or an amendment thereto may permit an Award
(other than an Incentive Stock Option) to be transferred to, exercised by and paid to certain persons or entities related to the Participant, including but not limited to members of the Participant’s family, charitable institutions, or trusts
or other entities whose beneficiaries or beneficial owners are members of the Participant’s family and/or charitable institutions, or to such other persons or entities as may be expressly approved by the Committee, pursuant to such conditions
and procedures as the Committee may establish. Any permitted transfer shall be subject to the condition that the Committee receive evidence satisfactory to it that the transfer is being made for estate and/or tax planning purposes (or to a
“blind trust” in connection with the Participant’s termination of employment or service with the Company or a Subsidiary to assume a position with a governmental, charitable, educational or similar non-profit institution) and on a
basis consistent with the Company’s lawful issue of securities. 
  
 9.5 BENEFICIARIES. Notwithstanding Section 9.4, a Participant may, in the manner determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to
any Award upon the Participant’s death. A beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the
Participant, except to the extent the Plan and Award Agreement otherwise provide, and to any additional restrictions deemed necessary or appropriate by the Committee. If the Participant is married and resides in a community property state, a
designation of a person other than the Participant’s spouse as his beneficiary with respect to more than 50% of the Participant’s interest in the Award shall not be effective without the prior written consent of the Participant’s
spouse. If no beneficiary has been designated or survives the Participant, payment shall be made to the person entitled thereto pursuant to the Participant’s will or the laws of descent and distribution. Subject to the foregoing, a beneficiary
designation may be changed or revoked by a Participant at any time provided the change or revocation is filed with the Committee. 
  

 13 

 9.6 STOCK CERTIFICATES. Notwithstanding anything herein to the contrary, the Company shall
not be required to issue or deliver any certificates evidencing shares of Stock pursuant to the exercise of any Award, unless and until the Board has determined, with advice of counsel, that the issuance and delivery of such certificates is in
compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed or traded. All Stock certificates delivered pursuant to the Plan are subject to
any stop-transfer orders and other restrictions as the Committee deems necessary or advisable to comply with federal, state, or foreign jurisdiction, securities or other laws, rules and regulations and the rules of any national securities exchange
or automated quotation system on which the Stock is listed, quoted, or traded. The Committee may place legends on any Stock certificate to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the
Board may require that a Participant make such reasonable covenants, agreements, and representations as the Board, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements. The Committee shall have the
right to require any Participant to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Committee. 
  
 ARTICLE 10 
 CHANGES IN CAPITAL STRUCTURE 
  
 10.1 ADJUSTMENTS. In the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation, spin-off, recapitalization or other distribution (other than normal cash
dividends) of Company assets to stockholders, or any other change affecting the shares of Stock or the share price of the Stock, the Committee shall make such proportionate adjustments, if any, as the Committee in its discretion may deem appropriate
to reflect such change with respect to (i) the aggregate number and type of shares that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Sections 3.1 and 3.3); (ii) the terms and conditions of any
outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto); and (iii) the grant or exercise price per share for any outstanding Awards under the Plan. Any adjustment affecting an Award
intended as Qualified Performance-Based Compensation shall be made consistent with the requirements of Section 162(m) of the Code. 
  
 10.2 ACCELERATION UPON A CHANGE OF CONTROL. If a Change of Control occurs and a Participant’s Awards are not converted, assumed, or
replaced by a successor, the Committee in its sole discretion may provide that all Awards shall become fully exercisable and all forfeiture restrictions on such Awards shall lapse. To the extent that this provision causes Incentive Stock Options to
exceed the dollar limitation set forth in Section 5.2(c), the excess Options shall be deemed to be Non-Qualified Stock Options. Upon, or in anticipation of, a Change in Control, the Committee may cause any and all Awards outstanding hereunder to
terminate at a specific time in the future and shall give each Participant the right to exercise such Awards during a period of time as the Committee, in its sole and absolute discretion, shall determine. 
  
 10.3 OUTSTANDING AWARDS – CERTAIN MERGERS. Subject to any
required action by the stockholders of the Company, in the event that the Company shall be the 
  

 14 

 surviving corporation in any merger or consolidation (except a merger or consolidation as a result of which the holders
of shares of Stock receive securities of another corporation), each Award outstanding on the date of such merger or consolidation shall pertain to and apply to the securities that a holder of the number of shares of Stock subject to such Award would
have received in such merger or consolidation. 
  
 10.4
OUTSTANDING AWARDS – OTHER CHANGES. In the event of any other change in the capitalization of the Company or corporate change other than those specifically referred to in this Article 10, the Committee may, in its absolute
discretion, make such adjustments in the number and class of shares subject to Awards outstanding on the date on which such change occurs and in the per share grant or exercise price of each Award as the Committee may consider appropriate to prevent
dilution or enlargement of rights. 
  
 10.5 NO OTHER
RIGHTS. Except as expressly provided in the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of
shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Committee under the Plan, no issuance by the
Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of shares of Stock subject to an Award or the grant or
exercise price of any Award. 
  
 ARTICLE 11 
 ADMINISTRATION 
  
 11.1 COMMITTEE. The Plan shall be administered by the Compensation Committee of the Board. After the Public Trading Date the Committee shall
consist of at least two individuals, each of whom qualifies as (i) a Non-Employee Director, and (ii) an “outside director” pursuant to Code Section 162(m) and the regulations issued thereunder. Reference to the Committee shall refer to the
Board if the Compensation Committee ceases to exist and the Board does not appoint a successor Committee. 
  
 11.2 ACTION BY THE COMMITTEE. A majority of the Committee shall constitute a quorum. The acts of a majority of the members present at any
meeting at which a quorum is present, and acts approved in writing by a majority of the Committee in lieu of a meeting, shall be deemed the acts of the Committee. Each member of the Committee is entitled to, in good faith, rely or act upon any
report or other information furnished to that member by any officer or other employee of the Company or any Subsidiary, the Company’s independent certified public accountants, or any executive compensation consultant or other professional
retained by the Company to assist in the administration of the Plan. 
  
 11.3 AUTHORITY OF COMMITTEE. Subject to any specific designation in the Plan, the Committee has the exclusive power, authority and discretion to: 
  

	 	(a)	Designate Participants to receive Awards; 

  

	 	(b)	Determine the type or types of Awards to be granted to each Participant; 

  

 15 

 (c) Determine the number of Awards to be granted and the number of shares of Stock to which an Award will
relate; 
  
 (d) Determine the terms and conditions of any Award
granted pursuant to the Plan, including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations on the Award, any schedule for lapse of forfeiture restrictions or restrictions on
the exercisability of an Award, and accelerations or waivers thereof, any provisions related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Committee in its sole discretion determines;
provided, however, that the Committee shall not have the authority to accelerate the vesting or waive the forfeiture of any Performance-Based Awards; 
  
 (e) Determine whether, to what extent, and pursuant to what circumstances an Award may be settled in, or the exercise price of an Award may be paid in,
cash, Stock, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered; 
  
 (f) Prescribe the form of each Award Agreement, which need not be identical for each Participant; 
  
 (g) Decide all other matters that must be determined in connection with an
Award; 
  
 (h) Establish, adopt, or revise any rules and
regulations as it may deem necessary or advisable to administer the Plan; 
  
 (i) Interpret the terms of, and any matter arising pursuant to, the Plan or any Award Agreement; and 
  
 (j) Make all other decisions and determinations that may be required pursuant to the Plan or as the Committee deems necessary or advisable to administer
the Plan. 
  
 11.4 DECISIONS BINDING. The
Committee’s interpretation of the Plan, any Awards granted pursuant to the Plan, any Award Agreement and all decisions and determinations by the Committee with respect to the Plan are final, binding, and conclusive on all parties. 

 
 ARTICLE 12 
 EFFECTIVE AND EXPIRATION DATE 
  
 12.1 EFFECTIVE DATE. The Plan is effective as of the date the Plan is approved by the Company’s stockholders (the “Effective Date”). The Plan will be deemed to be approved by the
stockholders if it receives the affirmative vote of the holders of a majority of the shares of stock of the Company present or represented and entitled to vote at a meeting duly held in accordance with the applicable provisions of the Company’s
Bylaws. 
  
 12.2 EXPIRATION DATE. The Plan will
expire on, and no Award may be granted pursuant to the Plan after, the tenth anniversary of the Effective Date. Any Awards that are outstanding on the tenth anniversary of the Effective Date shall remain in force according to the terms of the Plan
and the applicable Award Agreement. 
  

 16 

 ARTICLE 13 
 AMENDMENT, MODIFICATION, AND TERMINATION 
  
 13.1 AMENDMENT, MODIFICATION, AND TERMINATION. With the approval of the Board, at any time and from time to time, the Committee may terminate, amend or modify the Plan; provided, however, that (i)
to the extent necessary and desirable to comply with any applicable law, regulation, or stock exchange rule, the Company shall obtain stockholder approval of any Plan amendment in such a manner and to such a degree as required, and (ii) shareholder
approval is required for any amendment to the Plan that (A) increases the number of shares available under the Plan (other than any adjustment as provided by Article 11), (B) permits the Committee to grant Options with an exercise price that is
below Fair Market Value on the date of grant, or (C) permits the Committee to extend the exercise period for an Option beyond ten years from the date of grant. 
  

13.2 AWARDS PREVIOUSLY GRANTED. No termination, amendment, or modification of the Plan shall adversely affect in any material way any
Award previously granted pursuant to the Plan without the prior written consent of the Participant. 
  
 ARTICLE 14 
 GENERAL PROVISIONS 
  
 14.1 NO RIGHTS TO AWARDS. No Participant, employee, or other
person shall have any claim to be granted any Award pursuant to the Plan, and neither the Company nor the Committee is obligated to treat Participants, employees, and other persons uniformly. 
  
 14.2 NO STOCKHOLDERS RIGHTS. No Award gives the Participant any
of the rights of a stockholder of the Company unless and until shares of Stock are in fact issued to such person in connection with such Award. 
  
 14.3 WITHHOLDING. The Company or any Subsidiary shall have the authority and the right to deduct or withhold, or require a Participant to
remit to the Company, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant’s FICA obligation) required by law to be withheld with respect to any taxable event concerning a Participant arising as a
result of this Plan. The Committee may in its discretion and in satisfaction of the foregoing requirement allow a Participant to elect to have the Company withhold shares of Stock otherwise issuable under an Award (or allow the return of shares of
Stock) having a Fair Market Value equal to the sums required to be withheld. Notwithstanding any other provision of the Plan, the number of shares of Stock which may be withheld with respect to the issuance, vesting, exercise or payment of any Award
(or which may be repurchased from the Participant of such Award within six months after such shares of Stock were acquired by the Participant from the Company) in order to satisfy the Participant’s federal, state, local and foreign income and
payroll tax liabilities with respect to the issuance, vesting, exercise or payment of the Award shall be limited to the number of shares which have a Fair Market Value on the date of withholding or repurchase equal to the aggregate amount of such
liabilities based on the minimum statutory withholding rates for federal, state, local and foreign income tax and payroll tax purposes that are applicable to such supplemental taxable income. 
  

 17 

 14.4 NO RIGHT TO EMPLOYMENT OR SERVICES. Nothing in the Plan or any Award Agreement shall
interfere with or limit in any way the right of the Company or any Subsidiary to terminate any Participant’s employment or services at any time, nor confer upon any Participant any right to continue in the employ or service of the Company or
any Subsidiary. 
  
 14.5 UNFUNDED STATUS OF AWARDS.
The Plan is intended to be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Participant any
rights that are greater than those of a general creditor of the Company or any Subsidiary. 
  
 14.6 INDEMNIFICATION. To the extent allowable pursuant to applicable law, each member of the Committee or of the Board shall be indemnified and held harmless by the Company from any loss, cost,
liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any
action or failure to act pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her, provided he or she gives the Company an opportunity,
at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such
persons may be entitled pursuant to the Company’s Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless. 
  
 14.7 RELATIONSHIP TO OTHER BENEFITS. No payment pursuant to the
Plan shall be taken into account in determining any benefits pursuant to any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except to the extent otherwise expressly
provided in writing in such other plan or an agreement thereunder. 
  
 14.8 EXPENSES. The expenses of administering the Plan shall be borne by the Company and its Subsidiaries. 
  
 14.9 TITLES AND HEADINGS. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any
conflict, the text of the Plan, rather than such titles or headings, shall control. 
  
 14.10 FRACTIONAL SHARES. No fractional shares of Stock shall be issued and the Committee shall determine, in its discretion, whether cash shall be given in lieu of fractional shares or whether such
fractional shares shall be eliminated by rounding up or down as appropriate. 
  
 14.11 LIMITATIONS APPLICABLE TO SECTION 16 PERSONS. Notwithstanding any other provision of the Plan, the Plan, and any Award granted or awarded to any Participant who is then subject to Section 16 of the
Exchange Act, shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the 
  

 18 

 Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of
such exemptive rule. To the extent permitted by applicable law, the Plan and Awards granted or awarded hereunder shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. 
  
 14.12 GOVERNMENT AND OTHER REGULATIONS. The obligation of the
Company to make payment of awards in Stock or otherwise shall be subject to all applicable laws, rules, and regulations, and to such approvals by government agencies as may be required. The Company shall be under no obligation to register pursuant
to the Securities Act of 1933, as amended, any of the shares of Stock paid pursuant to the Plan. If the shares paid pursuant to the Plan may in certain circumstances be exempt from registration pursuant to the Securities Act of 1933, as amended, the
Company may restrict the transfer of such shares in such manner as it deems advisable to ensure the availability of any such exemption. 
  
 14.13 GOVERNING LAW. The Plan and all Award Agreements shall be construed in accordance with and governed by the laws of the State of
Delaware. 
  
 * * * * 
  
 I hereby certify that the foregoing Plan was duly adopted by the Board of
Directors of Reliant Pharmaceuticals, Inc. on April 1, 2004 and approved by the shareholders of Reliant Pharmaceuticals, Inc. by written action on April 15, 2004. 
  
 Executed on this 1st day of April, 2004. 
  

	
	 /s/ Michael Lerner

	 Secretary

  

 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]